These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37995739)

  • 41. Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases.
    Udaondo C; Cámara C; Miguel Berenguel L; Alcobendas Rueda R; Muñoz Gómez C; Millán Longo C; Díaz-Delgado B; Falces-Romero I; Díaz Almirón M; Ochando J; Méndez-Echevarría A; Remesal Camba A; Calvo C
    Pediatr Rheumatol Online J; 2022 Aug; 20(1):64. PubMed ID: 35964130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
    Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
    Front Immunol; 2022; 13():892277. PubMed ID: 35669765
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine.
    Agrati C; Castilletti C; Goletti D; Sacchi A; Bordoni V; Mariotti D; Notari S; Matusali G; Meschi S; Petrone L; Aiello A; Najafi Fard S; Farroni C; Colavita F; Lapa D; Leone S; Agresta A; Capobianchi M; Ippolito G; Vaia F; Puro V;
    Sci Rep; 2022 Apr; 12(1):6687. PubMed ID: 35461335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals.
    Cavic M; Nesic A; Mirjacic Martinovic K; Vuletic A; Besu Zizak I; Tisma Miletic N; Krivokuca A; Jankovic R; Gavrovic-Jankulovic M
    Sci Rep; 2023 Apr; 13(1):6271. PubMed ID: 37069315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
    Kato H; Miyakawa K; Ohtake N; Yamaoka Y; Yajima S; Yamazaki E; Shimada T; Goto A; Nakajima H; Ryo A
    Vaccine; 2022 Apr; 40(19):2652-2655. PubMed ID: 35370020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients.
    Blazquez-Navarro A; Safi L; Meister TL; Thieme CJ; Kaliszczyk S; Paniskaki K; Stockhausen M; Hörstrup J; Cinkilic O; Flitsch-Kiefner L; Marheinecke C; Steinmann E; Seibert FS; Stervbo U; Westhoff TH; Pfaender S; Roch T; Babel N
    Kidney Int; 2021 Sep; 100(3):698-700. PubMed ID: 34273381
    [No Abstract]   [Full Text] [Related]  

  • 48. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
    Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():839922. PubMed ID: 35309303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study.
    Van Praet J; Reynders M; De Bacquer D; Viaene L; Schoutteten MK; Caluwé R; Doubel P; Heylen L; De Bel AV; Van Vlem B; Steensels D; De Vriese AS
    J Am Soc Nephrol; 2021 Dec; 32(12):3208-3220. PubMed ID: 34588184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients.
    Bader G; Itan M; Edry-Botzer L; Cohen H; Haskin O; Mozer-Glassberg Y; Harel L; Munitz A; Mandelblit NM; Gerlic M
    Front Immunol; 2023; 14():1131965. PubMed ID: 37051242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
    J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine.
    Gallais F; Gantner P; Planas D; Solis M; Bruel T; Pierre F; Soulier E; Rossolillo P; Fourati S; Sibilia J; Schwartz O; Fafi-Kremer S
    Front Immunol; 2022; 13():790212. PubMed ID: 35281046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Choi SH; Park JY; Kweon OJ; Park JH; Kim MC; Lim Y; Chung JW
    J Korean Med Sci; 2023 May; 38(20):e155. PubMed ID: 37218354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.
    Yau K; Kurtesi A; Qi F; Delgado-Brand M; Tursun TR; Hu Q; Dhruve M; Kandel C; Enilama O; Levin A; Jiang Y; Hardy WR; Yuen DA; Perl J; Chan CT; Leis JA; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Nat Commun; 2023 Sep; 14(1):6041. PubMed ID: 37758707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.
    Yoshida M; Kobashi Y; Kawamura T; Shimazu Y; Nishikawa Y; Omata F; Saito H; Yamamoto C; Zhao T; Takita M; Ito N; Tatsuno K; Kaneko Y; Nakayama A; Kodama T; Wakui M; Takahashi K; Tsubokura M
    Sci Rep; 2023 Jun; 13(1):9264. PubMed ID: 37286720
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
    J Infect; 2022 Jul; 85(1):e24-e25. PubMed ID: 35398406
    [No Abstract]   [Full Text] [Related]  

  • 58. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
    Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response.
    Wang X; Yuen TT; Dou Y; Hu J; Li R; Zeng Z; Lin X; Gong H; Chan CH; Yoon C; Shuai H; Ho DT; Hung IF; Zhang BZ; Chu H; Huang JD
    Nat Commun; 2023 Jun; 14(1):3440. PubMed ID: 37301910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.